By combining the advantages of upcyte hepatocytes with INDIGO’s industry-leading platform and science, the new hepatotoxicty assay kit helps researchers get the information they need to confidently advance their discovery processes.
INDIGO Biosciences Announces Release of Gene Expression Kit Utilizing upcyte® Hepatocytes
Portfolio Expansion Helps Researchers Move to the Next Stage of Discovery Faster State College, PA (December 5, 2018) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte® hepatocytes to their portfolio. This addition both complements INDIGO’s industry-leading nuclear receptor assays andRead More
INDIGO Biosciences Receives Stephen M. Goodman Award from Keiretsu Forum
Most Valued Company Award Presented During Angel Capital Expo State College, PA (October 30, 2017) – INDIGO Biosciences, Inc. is pleased to announce that it was awarded the Stephen M. Goodman Most Valued Company Award at the Keiretsu Forum Angel Capital Expo. The Expo took place October 19, 2017 at the Union League in Philadelphia,Read More
INDIGO Announces Relaunch of Nuclear Receptor Resource Website
Premiere Educational Resource for Human Nuclear Receptor Information State College, PA (12/8/2016) INDIGO Biosciences, Inc. is pleased to announce the relaunch of the Nuclear Receptor Resource website. The NRR is a premier educational resource for information on the 48 human nuclear receptors. The NRR website has undergone a major redesign to make the site easierRead More
INDIGO Biosciences and Bertin Pharma Sign European Distribution Agreement
Ready-to-Use Nuclear Receptor Assay kits for over 20 disease states, including Cardiovascular and Metabolic Disease, Cancer, and Inflammation State College, PA (November 15, 2016) INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and Bertin Pharma have announced the completion of a European distribution agreement. Over 40 product references for studying nuclear receptors are nowRead More
INDIGO Offers Expansion of Industry-Leading FXR Assay
Meets industry demand for increased pre-clinical predictability. State College, PA (August 9, 2016) INDIGO Biosciences, the recognized industry leader in Nuclear Receptor research, announced the addition of the Mouse Farnesoid X Receptor (mFXR) assay to their FXR portfolio. This addition both complements INDIGO’s industry-leading human FXR assay and meets the demand for an expansion ofRead More
INDIGO Biosciences Raises $500 Thousand in Series B Funding
A Combination of Private Equity and Public Funds Invested State College, PA (August 2, 2016)– INDIGO Biosciences announced the completion of a $500,000 Series B financing round on June 28, 2016. The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) and AGSM, a private equity investment firm from Pittsburgh, Pennsylvania led this round. INDIGO’S latest financing willRead More
INDIGO Announces upcyte® Product Agreement
Agreement meets increasing demand for predictive liver toxicity models. State College, PA (July 19, 2016) INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and upcyte® technologies GmbH announced completion of a distribution Partnership. upcyte® technologies GmbH, based in Hampburg-Eppendorf, Germany, is a life science company specializing in controlled, scalable propagation and standardization of human primaryRead More
INDIGO Offers Next Generation in PXR Assay Systems
Expansion of Assay Critical to the Study of Metabolism and Drug-Drug Interactions State College, PA (June 7, 2016) INDIGO Biosciences, a recognized industry-leading provider of nuclear receptor products and services, announced today that it has completed development of the next generation of Pregnane X Receptor (PXR) technology. Previously available in kits and services for onlyRead More
Indigo Announces In Vitro Toxicology Platform
In vitro toxicology platform provides predictive model of liver toxicity. Aims to reduce the high rates of drug-induced liver damage State College, PA (May 4, 2016) INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has completed development of an in vitro toxicology platform, meeting the demand for predictive liver toxicity models. INDIGO’s inRead More